Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands |
Mar. 31, 2023 |
Dec. 31, 2022 |
---|---|---|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Other | $ 2,191 | $ 3,080 |
Total accrued expenses and other current liabilities | 12,393 | 14,764 |
Supply Agreement | Vaxcyte | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Collaboration and license agreements and supply agreement accruals | 5,274 | 4,830 |
CMO | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Collaboration and license agreements and supply agreement accruals | 2,404 | 3,900 |
Clinical Trials | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Collaboration and license agreements and supply agreement accruals | $ 2,524 | $ 2,954 |
X | ||||||||||
- Definition Accrued expenses and other current liabilities. No definition available.
|
X | ||||||||||
- Definition Collaboration and license agreements and supply agreement accruals current. No definition available.
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|